Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of depletion of Zeb1 in CD11c+ dendritic cells

ABSTRACT: To investigate potential target genes of Zeb1 that were involved in regulation of antigen cross-presentation. We then performed gene expression profiling analysis using data obtained from RNA-seq from WT and Zeb1-deficient BMDC .

ORGANISM(S): Mus musculus

PROVIDER: GSE216059 | GEO | 2023/09/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effect of depletion of Zeb1 in CD11c+ dendritic cells [RNA-seq]

Project description:To investigate potential target genes of Zeb1 that were involved in regulation of antigen cross-presentation. We then performed gene expression profiling analysis using data obtained from RNA-seq from WT and Zeb1-deficient BMDC after HKLM-OVA stimulating for 4 hours.

2023-09-07 | GSE206963 | GEO

To find target genes of Zeb1 [CUT&Tag-Seq]

Project description:To investigate potential target genes of Zeb1 that were involved in regulation of antigen cross-presentation. We then performed CUT&tag about Zeb1 gene from WT BMDC after HKLM-OVA stimulating for 4 hours

2023-09-07 | GSE206964 | GEO

To find target miRNA of Zeb1

Project description:To investigate potential target miRNA of Zeb1 that were involved in regulation of antigen cross-presentation. We then performed gene expression profiling analysis using data obtained from miRNA-seq from WT and Zeb1-deficient BMDC after HKLM-OVA stimulating for 4 hours.

2023-09-07 | GSE207161 | GEO

Effect of depletion of Zeb1 in CD11c+ dendritic cells

Project description:Effect of depletion of Zeb1 in CD11c+ dendritic cells

| PRJNA891854 | ENA

Effect of depletion of Zeb1 in CD11c+ dendritic cells [RNA-seq]

Project description:Effect of depletion of Zeb1 in CD11c+ dendritic cells [RNA-seq]

| PRJNA853064 | ENA

Gene expression data in Bone Marrow Derived Dendritic Cells (BMDC) following nanoemulsion adjuvant exposure

Project description:Antigen uptake, processing and presentation by dendritic cells are regulated by complex intra- and inter-cellular signalling events. Typical vaccine adjuvants lead to the transcription of pro-inflammatory cytokines and chemokines which relate to immune induction. We used microarrays to detail the global expression of genes in BMDC underlying emulsion internalization and DC activation with a non-inflammatory nanoemulsion adjuvant. BMDC were incubated with 0.001% v/v naomeulsion (W805EC) or media alone for 6 hours. Total RNA was extracted per sample using RNA easy (Qiagen).

2010-11-18 | E-GEOD-25485 | biostudies-arrayexpress

Effect of Sec61 inhibitor mycolactone on the proteome of the MutuDC dendritic cell line

Project description:Here we used a newly identified Sec61 blocker, mycolactone, to analyze Sec61 contribution to antigen cross presentation, ERAD and transport of internalized antigens into the cytosol in dendritic cells. Shotgun proteomics were used to asses the broad-ranging effects of Sec61 blockade on dendritic cells and its effect on critical proteins required for antigen presentation and ERAD.

2017-07-11 | PXD006103 | Pride

Gene expression data in Bone Marrow Derived Dendritic Cells (BMDC) following nanoemulsion adjuvant exposure

2010-11-18 | GSE25485 | GEO

Compound screen identifies inhibitor of apoptosis proteins (IAP) antagonist as an inducer of T cell proliferation after cross-presentation by dendritic cells (Human)

Project description:Cross-presentation of tumor antigens by dendritic cells (DCs) is crucial to prime and (re-) stimulate CD8+ T cells. This process is important in initiating and maintaining an anti-tumor response. Here, we show that tumor presence of conventional type 1 DCs (cDC1), a subtype that excels in cross-presentation, correlates with response to neoadjuvant immune checkpoint blockade (ICB) in melanoma. This led us to hypothesize that patients failing to respond to ICB could benefit from enhanced cross-presentation of tumor antigens. We therefore established a cross-presentation assay to screen over 5,500 compounds for enhancers of DC cross-presentation using induced T cell proliferation as readout. We identified 145 enhancers, including AZD5582, an antagonist of inhibitor of apoptosis proteins (IAPs) cIAP1, cIAP2 and XIAP. AZD5582 treatment led to DC activation of the non-canonical nuclear factor kappa B (NF-kB) pathway, enhanced antigen import from endolysosomes into the cytosol and increased expression of genes involved in cross-presentation. Furthermore, it upregulated expression of CD80, CD86, MHC class II, CD70 and secretion of TNF by DCs. This enhanced DC activation and maturation program was observed also in tumor-bearing mice upon AZD5582 treatment, culminating into an increased frequency of systemic tumor antigen-specific CD8+ T cells. Our results merit further exploration of AZD5582 to increase antigen cross-presentation for improving the clinical benefit of ICB in unfavorable patients.

2023-03-23 | GSE217050 | GEO

Compound screen identifies inhibitor of apoptosis proteins (IAP) antagonist as an inducer of T cell proliferation after cross-presentation by dendritic cells (Mouse)

2023-03-23 | GSE217048 | GEO